Buscar
Mostrando ítems 1-10 de 87
Biological and nonbiological complex drugs for multiple sclerosis in Latin America: Regulations and risk management
(Taylor and Francis, 2015)
Biological drugs and nonbiological complex drugs with expired patents are followed by biosimilars and follow-on drugs that are supposedly similar and comparable with the reference product in terms of quality, safety and ...
New monoclonal antibody biosimilars approved in 2015 in Latin America: Position statement of the Latin American Forum on Biosimilars in biosimilarity, interchangeability and extrapolation of indications
(Pro Pharma Communications International, 2016-06)
Introduction: The Latin American Forum on Biosimilars (FLAB) is an annual meeting that brings together various stakeholders, including key opinion leaders, the pharmaceutical industry, academics, patients, lawyers and other ...
Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
(Springer, 2019)
The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient ...
Estudos de medicamentos biosimilares
(2010-09-01)
In Brazil, the registration of new drugs is carried out only when the regulatory agency (Anvisa, acronym in Portuguese) is fully satisfied with the evidence of their quality, efficacy and safety, presented by a pharmaceutical ...
Estudos de medicamentos biosimilares
(2010-09-01)
In Brazil, the registration of new drugs is carried out only when the regulatory agency (Anvisa, acronym in Portuguese) is fully satisfied with the evidence of their quality, efficacy and safety, presented by a pharmaceutical ...
Actualización en biosimilares : una reflexión sobre la reglamentación en Colombia de los medicamentos biológicos y biosimilaresBiosimilars update, a reflection on regulations in Colombia about biological and biosimilar medicines
(Asociación Colombiana de Dermatología y Cirugía DermatológicaCentro de de Investigaciones DermatológicasBogotá, Colombia, 2021)
Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients
(2021-01-01)
Background: In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients’ knowledge and perceptions regarding biosimilars and compare with viewpoints from non-Brazilian patients. Methods: An ...
Expression of cetuximab biosimilar for development of Immunonanoparticle: Strategies and targets for drug delivery proposal towards treatment of prostate cancer
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2021)
A bibliometric analysis of the global research on biosimilars
(BioMed Central, 2018)
Background: Biosimilars could be a promising option to help decrease healthcare costs and expand access to treatment. There is no previous evidence of a global bibliometric analysis on biosimilars. Therefore, we aimed to ...